Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked vigilantly but unsuccessfully to create an one-time therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination therapy in the treatment of multi-drug-resistant HIV have been closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my past few shares. My first CytoDyn article, “CytoDyn: What In order to Do When It is Too Good to be able to Be True?”, set away all of the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan presented such an extremely marketing image in the Uptick Newswire employment interview which I came away with a bad impression of the company.

Irony of irony, my poor viewpoint of the business enterprise has grown steadily, though the disappointment hasn’t been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this expertise as well as linked intellectual property from Progenics to CytoDyn, and also roughly 25 million mg of majority drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 zillion) and the very first brand new drug program approval ($5 million), and even royalty payments of 5 % of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and numerous therapies, it has this single therapies and a “broad pipeline of indications” as it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy of dozens of indications.

Its opening banner on its website (below) shows an active company with diverse interests albeit focused on leronlimab, several disease types, multiple publications in addition to multiple presentations.

Could all this be smoke and mirrors? That’s a question I’ve been asking myself through the really start of the interest of mine in this business. Judging by way of the multiples of thousands of diverse commentary on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this question.

CytoDyn is a traditional battleground, or perhaps some could say cult stock. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *